respiratory syncytial virus

News

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al

News

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan

News

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos

News

Moderna swings to loss as COVID sales slump

Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin

News

GSK grabs early lead in RSV vaccine race with Pfizer

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f

News

GSK targets younger age group with RSV jab Arexvy

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Moderna swings to loss as COVID sales slump

GSK grabs early lead in RSV vaccine race with Pfizer

GSK targets younger age group with RSV jab Arexvy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

respiratory syncytial virus

Editor's Picks